View Future GrowthPreveCeutical Medical 過去の業績過去 基準チェック /06PreveCeutical Medical は平均年間 12.8% の収益成長を遂げていますが、Pharmaceuticals 業界では年間 収益成長率 となっています。12.2% です。主要情報12.75%収益成長率16.75%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 23PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveceutical Medical Inc announced a non-brokered private placement of up to 40,000,000 units at an issue price of CAD 0.025 per unit for gross proceeds of CAD 1,000,000 on April 22, 2026. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.05 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.お知らせ • Aug 06PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveCeutical Medical Inc. announced a non-brokered private placement of up to 25,000,000 units at a price of CAD 0.04 per unit for gross proceeds of up to CAD 1,000,000 on August 5, 2025. Each unit consists of one common share and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.06 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the Canadian Securities Exchange.お知らせ • Jun 17PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025.お知らせ • Jun 12PreveCeutical Medical Inc. announced that it expects to receive CAD 0.75 million in fundingPreveceutical Medical Inc. announced a non-brokered private placement of up to 15,000,000 units at an issue price of CAD 0.05 per unit for gross proceeds of CAD 750,000 on June 11, 2025. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.08 for a period of 24 months from the closing of the offering. Finders' fees may be paid. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.お知らせ • May 23PreveCeutical Medical Inc. announced that it has received CAD 0.748383 million in fundingOn May 22, 2025, the PreveCeutical Medical Inc. closed the transaction by raising final tranche of CAD 158,382. In connection with the this tranche, the Company paid finders fees to an eligible finder comprised of CAD 12,670.56 in cash and issued 422,352 Finder’s Warrant. The Finder’s Warrant are exercisable into one additional Share at an exercise price of CAD 0.05 per share for 24 months from the closing of final tranche subject to the Acceleration Right. All securities issued in relation to the final tranche are subject to a hold period expiring four months and one day after closing in accordance with applicable securities laws.お知らせ • Sep 20PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD ApplicationPreveCeutical Medical Inc. announced that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats. The primary objectives of this study include: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain. This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain. Objective 2: Demonstrating the pharmacological relevance of brain CBD concentrations following intranasal application. Study Design: The research will be conducted through a series of well-structured experiments: Experiment 1: Rats will be administered up to three doses of CBD in sol-gel form via nasal spray. Evaluation will be carried out at six different time points. Brain regions such as the olfactory bulb, prefrontal cortex, parietal cortex, pons, and cerebellum will be assessed, and concentrations of CBD and its metabolites will be quantified using a validated LC-MS/MS assay. Experiment 2: A separate group of rats will receive intranasal CBD administration. Cerebrospinal fluid (CSF) and cardiac blood samples will be collected at specific time points based on the findings from Experiment 1. CBD and metabolite concentrations will be measured using validated LC-MS/MS assays. Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain. These are two conditions in which CBD has already demonstrated preclinical efficacy. Collaborative Efforts: Endosane is collaborating closely with the Brain and Mind Centre of the University of Sydney. A significant breakthrough in this partnership has been the identification of anandamide as a potential blood surrogate marker for CBD's brain activity. The research team has also examined the temporal changes in serum. PreveCeutical and Endosane dedication to research in the field of CBD delivery and pharmacology underscores its commitment to advancing medical knowledgeand improving patient outcomes. The company remains focused on scientific innovation, working diligently to pave the way for novel treatments and therapies.お知らせ • Jul 25PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and AustraliaPreveCeutical Medical Inc. announced that it is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021408143, and the European case has been allocated application no. EP21908152.8. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process.お知らせ • Jun 29PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses ThereofPreveCeutical Medical Inc. announced that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021384063, and the European case has been allocated application no. EP21893149.1. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in the US and Canada. The US case has been allocated the application no. US18/268951, and full filing details in Canada are awaited. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process. Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.収支内訳PreveCeutical Medical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PRVC.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Dec 250-23030 Sep 250-33030 Jun 250-32031 Mar 250-21031 Dec 240-11030 Sep 240-11030 Jun 240-11031 Mar 240-11031 Dec 230-11030 Sep 230-11030 Jun 230-11031 Mar 230-11031 Dec 220-11030 Sep 220-21030 Jun 220-11031 Mar 220-21031 Dec 210-21030 Sep 210-32030 Jun 210-22031 Mar 210-42031 Dec 200-42030 Sep 200-21-130 Jun 200-31131 Mar 200-31131 Dec 190-42230 Sep 190-92330 Jun 190-113331 Mar 190-124331 Dec 180-124230 Sep 180-96230 Jun 180-75231 Mar 180-84131 Dec 170-74130 Sep 170-63030 Jun 170-63031 Mar 170-33031 Dec 160-330質の高い収益: PRVC.Fは現在利益が出ていません。利益率の向上: PRVC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PRVC.Fは利益を出していないが、過去 5 年間で年間12.8%の割合で損失を削減してきた。成長の加速: PRVC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PRVC.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 1% ) と比較することは困難です。株主資本利益率高いROE: PRVC.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/21 04:15終値2026/08/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PreveCeutical Medical Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 23PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveceutical Medical Inc announced a non-brokered private placement of up to 40,000,000 units at an issue price of CAD 0.025 per unit for gross proceeds of CAD 1,000,000 on April 22, 2026. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.05 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.
お知らせ • Aug 06PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveCeutical Medical Inc. announced a non-brokered private placement of up to 25,000,000 units at a price of CAD 0.04 per unit for gross proceeds of up to CAD 1,000,000 on August 5, 2025. Each unit consists of one common share and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.06 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the Canadian Securities Exchange.
お知らせ • Jun 17PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025.
お知らせ • Jun 12PreveCeutical Medical Inc. announced that it expects to receive CAD 0.75 million in fundingPreveceutical Medical Inc. announced a non-brokered private placement of up to 15,000,000 units at an issue price of CAD 0.05 per unit for gross proceeds of CAD 750,000 on June 11, 2025. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.08 for a period of 24 months from the closing of the offering. Finders' fees may be paid. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.
お知らせ • May 23PreveCeutical Medical Inc. announced that it has received CAD 0.748383 million in fundingOn May 22, 2025, the PreveCeutical Medical Inc. closed the transaction by raising final tranche of CAD 158,382. In connection with the this tranche, the Company paid finders fees to an eligible finder comprised of CAD 12,670.56 in cash and issued 422,352 Finder’s Warrant. The Finder’s Warrant are exercisable into one additional Share at an exercise price of CAD 0.05 per share for 24 months from the closing of final tranche subject to the Acceleration Right. All securities issued in relation to the final tranche are subject to a hold period expiring four months and one day after closing in accordance with applicable securities laws.
お知らせ • Sep 20PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD ApplicationPreveCeutical Medical Inc. announced that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats. The primary objectives of this study include: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain. This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain. Objective 2: Demonstrating the pharmacological relevance of brain CBD concentrations following intranasal application. Study Design: The research will be conducted through a series of well-structured experiments: Experiment 1: Rats will be administered up to three doses of CBD in sol-gel form via nasal spray. Evaluation will be carried out at six different time points. Brain regions such as the olfactory bulb, prefrontal cortex, parietal cortex, pons, and cerebellum will be assessed, and concentrations of CBD and its metabolites will be quantified using a validated LC-MS/MS assay. Experiment 2: A separate group of rats will receive intranasal CBD administration. Cerebrospinal fluid (CSF) and cardiac blood samples will be collected at specific time points based on the findings from Experiment 1. CBD and metabolite concentrations will be measured using validated LC-MS/MS assays. Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain. These are two conditions in which CBD has already demonstrated preclinical efficacy. Collaborative Efforts: Endosane is collaborating closely with the Brain and Mind Centre of the University of Sydney. A significant breakthrough in this partnership has been the identification of anandamide as a potential blood surrogate marker for CBD's brain activity. The research team has also examined the temporal changes in serum. PreveCeutical and Endosane dedication to research in the field of CBD delivery and pharmacology underscores its commitment to advancing medical knowledgeand improving patient outcomes. The company remains focused on scientific innovation, working diligently to pave the way for novel treatments and therapies.
お知らせ • Jul 25PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and AustraliaPreveCeutical Medical Inc. announced that it is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021408143, and the European case has been allocated application no. EP21908152.8. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process.
お知らせ • Jun 29PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses ThereofPreveCeutical Medical Inc. announced that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021384063, and the European case has been allocated application no. EP21893149.1. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in the US and Canada. The US case has been allocated the application no. US18/268951, and full filing details in Canada are awaited. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process. Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.